BR0112925A - Peptìdeos apresentados por células - Google Patents

Peptìdeos apresentados por células

Info

Publication number
BR0112925A
BR0112925A BR0112925-2A BR0112925A BR0112925A BR 0112925 A BR0112925 A BR 0112925A BR 0112925 A BR0112925 A BR 0112925A BR 0112925 A BR0112925 A BR 0112925A
Authority
BR
Brazil
Prior art keywords
peptides
cell
determination
relates
present
Prior art date
Application number
BR0112925-2A
Other languages
English (en)
Inventor
Francis J Carr
Graham Carter
Koen Hellendoorn
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0112925A publication Critical patent/BR0112925A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"PEPTìDEOS APRESENTADOS POR CéLULAS". A presente invenção refere-se a métodos para determinar peptídeos apresentados sobre a superfície de células de mamífero após a adição às células de uma proteína. A presente invenção também refere-se a testes de diagnóstico baseados na determinação de tais peptídeos ou moléculas modificadas resultantes da determinação de tais peptídeos, tais como entidades farmacêuticas de preferência tendo atividade biológica específica e imunogenicidade reduzida ou aumentada quando comparada com as moléculas não modificadas correspondentes. Os métodos de acordo com esta invenção são de preferência estabelecidos com ferramentas usando-se espectroscopia de massa (MS).
BR0112925-2A 2000-08-03 2001-07-26 Peptìdeos apresentados por células BR0112925A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0018901.9A GB0018901D0 (en) 2000-08-03 2000-08-03 Peptides presented by cells
PCT/EP2001/008625 WO2002012899A2 (en) 2000-08-03 2001-07-26 Peptides presented by cells

Publications (1)

Publication Number Publication Date
BR0112925A true BR0112925A (pt) 2003-08-26

Family

ID=9896790

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112925-2A BR0112925A (pt) 2000-08-03 2001-07-26 Peptìdeos apresentados por células

Country Status (20)

Country Link
US (1) US20030171290A1 (pt)
EP (1) EP1305343B1 (pt)
JP (1) JP2004506202A (pt)
KR (1) KR20030037272A (pt)
CN (1) CN1511164A (pt)
AT (1) ATE306498T1 (pt)
AU (1) AU2001283958A1 (pt)
BR (1) BR0112925A (pt)
CA (1) CA2417767A1 (pt)
CZ (1) CZ2003464A3 (pt)
DE (1) DE60114018T2 (pt)
GB (1) GB0018901D0 (pt)
HU (1) HUP0301581A2 (pt)
MX (1) MXPA03000901A (pt)
NO (1) NO20030495D0 (pt)
PL (1) PL358874A1 (pt)
RU (1) RU2003105806A (pt)
SK (1) SK1982003A3 (pt)
WO (1) WO2002012899A2 (pt)
ZA (1) ZA200301637B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002023202A2 (en) * 2000-09-18 2002-03-21 Genzyme Corporation Method to identify antibody targets based on mass spectrometry (maldi-tof)
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
ATE386937T1 (de) * 2001-06-19 2008-03-15 Suntory Ltd Verfahren zur analyse eines in der zelle auftretenden proteins oder einer mit dem protein wechselwirkenden substanz
EP2481422A3 (en) * 2003-09-03 2013-04-03 Dendritherapeutics, Inc. Multiplex vaccines
AU2004283850C1 (en) 2003-10-16 2011-11-03 Amgen Research (Munich) Gmbh Multispecific deimmunized CD3-binders
US20090061478A1 (en) * 2006-01-30 2009-03-05 Lene Have Poulsen High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) * 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) * 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
CA2778552A1 (en) 2009-11-05 2011-05-12 Cephalon Australia Pty Ltd Treatment of cancer involving mutated kras or braf genes
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
WO2014184744A1 (en) * 2013-05-13 2014-11-20 Cellectis Methods for engineering highly active t cell for immunotherapy
US20170199961A1 (en) * 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
IL259023B (en) * 2016-09-30 2022-09-01 Cellex Life Sciences Incorporated Preparations containing protein-charged exosomes, methods for their production and uses thereof
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
JP2002534959A (ja) * 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
US6468537B1 (en) * 1999-04-28 2002-10-22 The Board Of Trustees Of Northwestern University Localization of major peptide autoepitopes for nucleosome specific T cells of systemic lupus erythematosus

Also Published As

Publication number Publication date
ATE306498T1 (de) 2005-10-15
KR20030037272A (ko) 2003-05-12
JP2004506202A (ja) 2004-02-26
CZ2003464A3 (cs) 2003-06-18
SK1982003A3 (en) 2003-08-05
GB0018901D0 (en) 2000-09-20
RU2003105806A (ru) 2004-07-20
EP1305343B1 (en) 2005-10-12
MXPA03000901A (es) 2003-06-24
WO2002012899A3 (en) 2002-11-07
CA2417767A1 (en) 2002-02-14
CN1511164A (zh) 2004-07-07
US20030171290A1 (en) 2003-09-11
AU2001283958A1 (en) 2002-02-18
DE60114018D1 (de) 2006-02-23
WO2002012899A2 (en) 2002-02-14
EP1305343A2 (en) 2003-05-02
NO20030495L (no) 2003-01-31
NO20030495D0 (no) 2003-01-31
PL358874A1 (en) 2004-08-23
ZA200301637B (en) 2004-02-03
DE60114018T2 (de) 2006-06-29
HUP0301581A2 (hu) 2003-08-28

Similar Documents

Publication Publication Date Title
BR0112925A (pt) Peptìdeos apresentados por células
Qin et al. Identification and characterization of posttranslational modifications of proteins by MALDI ion trap mass spectrometry
Pritzker et al. Deimination of myelin basic protein. 2. Effect of methylation of MBP on its deimination by peptidylarginine deiminase
György et al. Citrullination: a posttranslational modification in health and disease
Balza et al. Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin
Harcourt et al. A juxta-membrane epitope on the human acetylcholine receptor recognized by T cells in myasthenia gravis.
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
ATE420185T1 (de) Alzheimersche krankheit sekretase
BR9608558A (pt) Processos e usos de fator de crescimento de tecido conjuntivo como um agente de indução
AR038568A1 (es) Anticuerpos anti-a beta y su uso
BR9814276A (pt) Antìgenos de superfìcie
NZ323795A (en) Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides
CY1105446T1 (el) Διαγνωση και θepαπεια διαταραχων που συνδεονται με aur1 και aur2
BR9811039A (pt) Citocina de mamìferos: interleucina-b30 e reagentes relacionados
ES2133813T3 (es) Cadenas de lamininas: diagnostico y uso terapeutico.
Albérola et al. The amino-terminal part of human FLG2 is a component of cornified envelopes
BR9811675A (pt) Genes isolados para proteìna da membrana de célula dentrìtica
ES2173471T3 (es) Analisis para homocisteina y homocisteina desulfurasa a partir de tricomonas viginalis de protozoos.
BR122018077204B8 (pt) peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica
ATE277171T1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
Trask et al. Posttranslational modifications of microfibril associated glycoprotein-1 (MAGP-1)
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
BRPI0409736A (pt) anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados
BR9713450A (pt) Quimiocinas de mamìfero
AbdAlla et al. Structure of the bradykinin B2 receptors' amino terminus

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A,8A,9A E 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.